Scilex Holding Company is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain. Scilex Holding Company, formerly known as Vickers Vantage Corp. I, is based in PALO ALTO, Calif.
| Revenue (Most Recent Fiscal Year) | $30.25M |
| Net Income (Most Recent Fiscal Year) | $-358.73M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.95 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1236.33% |
| Net Margin (Trailing 12 Months) | -1185.78% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -178.57% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.08 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.07 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 3.72 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-24.94 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-36.45 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 8.49M |
| Free Float | 8.14M |
| Market Capitalization | $58.97M |
| Average Volume (Last 20 Days) | 0.04M |
| Beta (Past 60 Months) | 1.40 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.11% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.67% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |